Park et al. Risk-benefit of PJP propylaxis in rituximab treated patients. NNH 86 . NNT - all RTX 146, RTX+high dose steroid 21. This mirrors my practice @RheumNow #ACR22 Abstr#0720
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study - ACR Meeting Abstracts
